Testing for type-specific antibody to herpes simplex virus--implications for clinical practice.

F M Cowan

doi:10.1093/jac/45.suppl_4.9

Home/Archive/PubMed

PubMed · 10855767

Testing for type-specific antibody to herpes simplex virus--implications for clinical practice.

F M Cowan

View original source ↗Export metadata ↓

Abstract

Recently, assays that can distinguish between antibody to herpes simplex virus (HSV) types 1 and 2 have become available. These tests not only make it possible to better define infection in symptomatic patients and their sexual partners but also to identify asymptomatic infected individuals who may, nevertheless, be infectious. Type-specific antibody tests for HSV have several potential applications. They have a clear role in helping to define the worldwide distribution and pattern of HSV infection, and a potential role in the management of individual patients, although this has yet to be formally established and evaluated. Because of the high costs and potential disadvantages of targeted screening, particularly in the absence of effective interventions to prevent acquisition or transmission of infection, the public health benefits of screening need to be formally evaluated before its widespread introduction.

Explore related subjects

Antibodies, Viral Antibody Specificity Female Herpes Genitalis Herpes Simplex Herpesvirus 1, Human Herpesvirus 2, Human Humans Male Seroepidemiologic Studies Serologic Tests Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

F M Cowan. 2000. Testing for type-specific antibody to herpes simplex virus--implications for clinical practice.. https://doi.org/10.1093/jac%2F45.suppl_4.9

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Recombinant protein-based assays for detection of antibodies to severe acute respiratory syndrome coronavirus spike and nucleocapsid proteins.

Recombinant severe acute respiratory syndrome (SARS) nucleocapsid and spike protein-based immunoglobulin G immunoassays were developed and evaluated. Our assays demonstrated high sensitivity and specificity to the SARS coronavirus in sera collected from patients as late as 2 years postonset of symptoms. These assays will be useful not only for routine SARS coronavirus diagnostics but also for epidemiological and antibody kinetic studies.

Antibodies, Viral↗

PubMed2007

"There is such a thing as asking for trouble": taking rapid HIV testing to gay venues is fraught with challenges.

OBJECTIVES: To explore the feasibility and acceptability of offering rapid HIV testing to men who have sex with men in gay social venues. METHODS: Qualitative study with in-depth interviews and focus group discussions. Interview transcripts were analysed for recurrent themes. 24 respondents participated in the study. Six gay venue owners, four gay service users and one service provider took part in in-depth interviews. Focus groups were conducted with eight members of a rapid HIV testing clinic staff and five positive gay men. RESULTS: Respondents had strong concerns about confidentiality and privacy, and many felt that HIV testing was "too serious" an event to be undertaken in social venues. Many also voiced concerns about issues relating to post-test support and behaviour, and clinical standards. Venue owners also discussed the potential negative impact of HIV testing on social venues. CONCLUSION: There are currently substantial barriers to offering rapid HIV tests to men who have sex with men in social venues. Further work to enhance acceptability must consider ways of increasing the confidentiality and professionalism of testing services, designing appropriate pre-discussion and post-discussion protocols, evaluating different models of service delivery, and considering their cost-effectiveness in relation to existing services.

Antibodies, Viral↗

PubMed2007

Biological feasibility of developing prophylactic vaccines for viral pathogens: incubation period as a critical parameter.

Vaccines for sixteen major human viral pathogens have been approved for use in humans. For most other major human viral pathogens, the absence of an efficacious prophylactic vaccine is not for lack of effort. To identify the key parameters of biologic feasibility that determine "certainty-of-success" for developing prophylactic vaccines for major human viral pathogens, basic characteristics of viruses, such as primary genomic structure, route of transmission, and durability of viral infection were reviewed. These basic characteristics of viruses simply do not associate with successful vaccine development, so one must look elsewhere for characteristics predictive of successful vaccine development. Herein existing data are put forth in a way that demonstrates the impact of the combined effect of incubation period and broadly protective, relative immunogenicity on the "certainty-of-success" of developing effective vaccines for thirty viral pathogens. Both incubation period and broadly protective, relative immunogenicity appear to have accounted for much of the past successes in vaccine development, and may be useful in predicting where near term successes are most apt to occur.

Antibodies, Viral↗